RTP Mobile Logo
Submitted by jwr@researchtop... on Fri, 04/10/2020 - 13:33

Interview with James J Harding, MD

Track 1: Clinical experience with immune checkpoint inhibitors for patients with hepatocellular carcinoma (HCC)
Track 2: Immune-related adverse events associated with immune checkpoint inhibitors
Track 3: Activity of nivolumab or pembrolizumab as monotherapy for HCC
Track 4: Biologic rationale for combining immune checkpoint inhibitors and anti-angiogenic agents; results of the IMbrave150 study evaluating atezolizumab/bevacizumab as first-line therapy for unresectable HCC
Track 5: Side effects of the atezolizumab/bevacizumab combination in IMbrave150
Track 6: Risk of bleeding, cardiovascular disease, hypertension and proteinuria with the use of bevacizumab
Track 7: Perspective on the use of atezolizumab/bevacizumab for patients with liver dysfunction
Track 8: Objective response rate with atezolizumab/bevacizumab versus sorafenib in the IMbrave150 study
Track 9: Potential role of combination immunotherapy approaches versus locoregional modalities in the management of HCC
Track 10: Novel strategies under investigation for the treatment of HCC
Track 11: Case: A man in his early 50s with a history of hepatitis B receives atezolizumab/bevacizumab as first-line therapy for metastatic HCC
Track 12: Role of biopsy for patients with HCC; incidence of metastatic disease at first diagnosis
Track 13: Activity of atezolizumab/bevacizumab as first-line therapy
Track 14: Tolerability of the atezolizumab/bevacizumab combination
Track 15: Case: A man in his early 70s with metastatic HCC and nonalcoholic steatohepatitis-associated cirrhosis receives lenvatinib
Track 16: Use of immune checkpoint inhibitors for patients with preexisting autoimmune disease
Track 17: Efficacy and safety of lenvatinib in combination with pembrolizumab for patients with unresectable HCC
Track 18: Emerging data with nivolumab/ipilimumab and tremelimumab/durvalumab for advanced HCC
Track 19: Risks and benefits with anti-PD-1/PD-L1 and anti-CTLA-4 combinations versus immune checkpoint inhibitor and anti-angiogenic combinations
Track 20: Therapeutic options for patients with HCC in the second-line setting
Track 21: Case: A man in his early 70s with advanced hepatitis C-associated HCC receives cabozantinib after experiencing disease progression on sorafenib
Track 22: Perspective on the role of immune checkpoint inhibitors alone or in combination with anti-angiogenic therapy after disease progression on sorafenib
Track 23: Clinical experience with and management of tyrosine kinase inhibitor-associated toxicities
Track 24: Case: A woman in her late 70s with metastatic HCC develops myasthenia gravis after treatment with nivolumab
Track 25: Case: A woman in her late 50s with hepatitis B-associated metastatic HCC experiences a delayed response to nivolumab after enrolling in hospice care
Track 26: Delayed responses, pseudoprogression and hyperprogression associated with immune checkpoint inhibitors

Interview with Tim Greten, MD

Track 1: Adjuvant treatment of HCC: Prospect for immunotherapy
Track 2: Immune landscape of the liver and role of the microbiome
Track 3: Ongoing trials evaluating immunotherapy in the (neo)adjuvant setting for patients with HCC
Track 4: Role of immunotherapy and targeted therapy in the management of cholangiocarcinoma
Track 5: Mechanism for the synergy between immune checkpoint inhibitors and anti-angiogenic therapies
Track 6: Perspective on an antibody- versus a tyrosine kinase inhibitor-based approach to targeting VEGF
Track 7: Development of shellfish allergy after exposure to dual immune checkpoint blockade with durvalumab and tremelimumab
Track 8: Spectrum of immune-related adverse events associated with checkpoint inhibitors
Track 9: Background and design of the Phase III IMbrave150 trial
Track 10: Exclusion of patients with bleeding or high risk of bleeding with untreated varices from the IMbrave150 trial
Track 11: IMbrave150: Activity and tolerability of atezolizumab/bevacizumab versus sorafenib
Track 12: Historical response rates with single-agent tyrosine kinase inhibitors or anti-PD-1/PD-L1 antibodies
Track 13: Potential clinical role of atezolizumab/bevacizumab as first-line therapy for patients with advanced HCC
Track 14: Selection and sequencing of therapies for patients with HCC
Track 15: Ongoing investigation of immune checkpoint inhibitor combinations
Track 16: Activity of immune checkpoint inhibitors in patients with HCC
Track 17: Case: A man in his mid-60s with a history of hepatitis C receives cabozantinib for metastatic HCC after experiencing disease progression on lenvatinib and pembrolizumab
Track 18: Side effects associated with sorafenib and lenvatinib
Track 19: Efficacy and tolerability of pembrolizumab for HCC
Track 20: Approach to first- and second-line treatment for HCC
Track 21: Case: A man in his early 40s with chronic hepatitis B and metastatic HCC has no evidence of disease after treatment with pembrolizumab and surgical resection
Track 22: Case: A man in his mid-40s with uncontrolled hepatitis C develops transaminitis after treatment with sorafenib for HCC
 
FACULTY
 
James J Harding, MD
Assistant Attending
Gastrointestinal Oncology Service
Early Drug Development Service
Memorial Sloan Kettering Cancer Center
New York, New York
 
Tim Greten, MD
Bethesda, Maryland
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida